Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Neoplasm, Residual × eribulin × 1 year × Clear all

Sponsor

Conditions

Breast Neoplasms 24 Triple Negative Breast Neoplasms 10 Sarcoma 5 Neoplasm Metastasis 5 Liposarcoma 3 Inflammatory Breast Neoplasms 3 Urinary Bladder Neoplasms 2 Leiomyosarcoma 2 Carcinoma, Transitional Cell 2 Uterine Cervical Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Refractory Solid Tumors 1 Recurrence 1 Ketosis 1 Histiocytoma, Malignant Fibrous 1 Hemangiosarcoma 1 Hemangioendothelioma, Epithelioid 1 HR+HER2- Breast Cancer 1 HER2-negative Metastatic Breast Cancer 1 HER2-low Breast Cancer 1 Fludzoparib" and Anti-angiogenic 1 Colorectal Neoplasms 1 Brest Cancer 1 Brain Neoplasms 1 Advanced Breast Cancer 1

Interventions

Cyclophosphamide 11 blinatumomab 8 fludarabine 7 venetoclax 6 fludarabine phosphate 5 Cytarabine 5 Rituximab 4 Lenalidomide 4 Dexamethasone 4 Blood Specimen Collection 4 Azacitidine 4 obinutuzumab 3 daratumumab 3 pembrolizumab 2 nilotinib 2 Vincristine 2 Radiotherapy 2 Methotrexate 2 Melphalan 2 Immunotherapy, Adoptive 2 Imatinib Mesylate 2 Idarubicin 2 Daunorubicin 2 Dasatinib 2 Chemotherapy, Adjuvant 2 trastuzumab deruxtecan 1 tislelizumab 1 tisagenlecleucel 1 thymoglobulin 1 tetrathiomolybdate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡